丙戊酸在治疗儿童癫痫中的安全性研究现况
Safety of Valproic Acid in the Treatment of Children with Epilepsy
DOI: 10.12677/acm.2024.1482317, PDF,   
作者: 王鑫鹏, 蒋 莉*：重庆医科大学附属儿童医院神经内科，国家儿童健康与疾病临床医学研究中心，儿童发育疾病研究教育部重点实验室，儿科学重庆市重点实验室，重庆
关键词: 丙戊酸；儿童癫痫；安全性；Valproic Acid； Epilepsy of Children； Safety
摘要: 丙戊酸作为一种经典的广谱抗癫痫药，具有多种抗癫痫机制，被广泛的用于治疗几乎所有类型的癫痫及癫痫综合征。尽管大量的研究已证明丙戊酸具有良好的安全性，但因儿童群体有着不同于成人的生理及药物代谢特点，一些药物不良反应，特别是与年龄相关的药物不良反应仍限制了其应用。因此，本文围绕丙戊酸的药理作用、药代谢动力学、儿童药物代谢特点以及成人与儿童药物不良反应的异同来对丙戊酸在治疗儿童癫痫中的安全性作出综述。
Abstract: Valproic acid (VPA), as a broad-spectrum antiepileptic drug, is widely used in the treatment of almost all types of seizure, epilepsy and epilepsy syndrome due to its multiple mechanisms of action. Although numerous studies suggest the acceptable safety profile of VPA, some adverse drug reactions, especially those age-dependent, limit its application in children as the physiological and drug metabolism characteristics of children are different from adults. Herein, this article reviews the safety of VPA in the treatment of childhood by focusing on its action mechanisms, pharmacokinetics, characteristics of drug metabolism in children and similarities and differences of adverse drug reactions in adults and children.
文章引用：王鑫鹏, 蒋莉. 丙戊酸在治疗儿童癫痫中的安全性研究现况[J]. 临床医学进展, 2024, 14(8): 1031-1037. https://doi.org/10.12677/acm.2024.1482317

参考文献

[1] Fisher, R.S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J.H., Elger, C.E., et al. (2014) ILAE Official Report: A Practical Clinical Definition of Epilepsy. Epilepsia, 55, 475-482. [Google Scholar] [CrossRef] [PubMed]
[2] Löscher, W., Potschka, H., Sisodiya, S.M. and Vezzani, A. (2020) Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacological Reviews, 72, 606-638. [Google Scholar] [CrossRef] [PubMed]
[3] Mac, T.L., Tran, D., Quet, F., Odermatt, P., Preux, P. and Tan, C.T. (2007) Epidemiology, Aetiology, and Clinical Management of Epilepsy in Asia: A Systematic Review. The Lancet Neurology, 6, 533-543. [Google Scholar] [CrossRef] [PubMed]
[4] Dennis, M., Spiegler, B.J., Juranek, J.J., Bigler, E.D., Snead, O.C. and Fletcher, J.M. (2013) Age, Plasticity, and Homeostasis in Childhood Brain Disorders. Neuroscience & Biobehavioral Reviews, 37, 2760-2773. [Google Scholar] [CrossRef] [PubMed]
[5] Hunter, M.B., Yoong, M., Sumpter, R.E., Verity, K., Shetty, J., McLellan, A., et al. (2019) Neurobehavioral Problems in Children with Early-Onset Epilepsy: A Population-Based Study. Epilepsy & Behavior, 93, 87-93. [Google Scholar] [CrossRef] [PubMed]
[6] Steriade, C., French, J. and Devinsky, O. (2020) Epilepsy: Key Experimental Therapeutics in Early Clinical Development. Expert Opinion on Investigational Drugs, 29, 373-383. [Google Scholar] [CrossRef] [PubMed]
[7] Romoli, M., Mazzocchetti, P., D’Alonzo, R., Siliquini, S., Rinaldi, V.E., Verrotti, A., et al. (2019) Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. Current Neuropharmacology, 17, 926-946. [Google Scholar] [CrossRef] [PubMed]
[8] Tomson, T., Battino, D. and Perucca, E. (2016) Valproic Acid After Five Decades of Use in Epilepsy: Time to Reconsider the Indications of a Time-Honoured Drug. The Lancet Neurology, 15, 210-218. [Google Scholar] [CrossRef] [PubMed]
[9] Cofini, M., Quadrozzi, F., Favoriti, P., Favoriti, M. and Cofini, G. (2015) Valproic Acid-Induced Acute Pancreatitis in Pediatric Age: Case Series and Review of Literature. Il Giornale di chirurgia, 36, 158-160.
[10] Rinaldi, T., Kulangara, K., Antoniello, K. and Markram, H. (2007) Elevated NMDA Receptor Levels and Enhanced Postsynaptic Long-Term Potentiation Induced by Prenatal Exposure to Valproic Acid. Proceedings of the National Academy of Sciences of the United States of America, 104, 13501-13506. [Google Scholar] [CrossRef] [PubMed]
[11] Chateauvieux, S., Morceau, F., Dicato, M. and Diederich, M. (2010) Molecular and Therapeutic Potential and Toxicity of Valproic Acid. Journal of Biomedicine and Biotechnology, 2010, Article ID: 479364. [Google Scholar] [CrossRef] [PubMed]
[12] Nalivaeva, N.N., Belyaev, N.D. and Turner, A.J. (2009) Sodium Valproate: An Old Drug with New Roles. Trends in Pharmacological Sciences, 30, 509-514. [Google Scholar] [CrossRef] [PubMed]
[13] Ghiglieri, V., Sgobio, C., Patassini, S., Bagetta, V., Fejtova, A., Giampà, C., et al. (2010) TrkB/BDNF-Dependent Striatal Plasticity and Behavior in a Genetic Model of Epilepsy: Modulation by Valproic Acid. Neuropsychopharmacology, 35, 1531-1540. [Google Scholar] [CrossRef] [PubMed]
[14] 张恩慧, 张鹤声, 陈雨婕, 等. 广谱药物的“广谱”作用: 论丙戊酸在癫痫及共患病中的应用[J]. 癫痫杂志, 2023, 9(5): 393-399.
[15] Patsalos, P.N., Zugman, M., Lake, C., James, A., Ratnaraj, N. and Sander, J.W. (2017) Serum Protein Binding of 25 Antiepileptic Drugs in a Routine Clinical Setting: A Comparison of Free Non-Protein‐Bound Concentrations. Epilepsia, 58, 1234-1243. [Google Scholar] [CrossRef] [PubMed]
[16] Shen, X., Chen, X., Lu, J., Chen, Q., Li, W., Zhu, J., et al. (2022) Pharmacogenetics-Based Population Pharmacokinetic Analysis and Dose Optimization of Valproic Acid in Chinese Southern Children with Epilepsy: Effect of ABCB1 Gene Polymorphism. Frontiers in Pharmacology, 13, Article 1037239. [Google Scholar] [CrossRef] [PubMed]
[17] Xu, S., Chen, Y., Zhao, M., Guo, Y., Wang, Z. and Zhao, L. (2018) Population Pharmacokinetics of Valproic Acid in Epileptic Children: Effects of Clinical and Genetic Factors. European Journal of Pharmaceutical Sciences, 122, 170-178. [Google Scholar] [CrossRef] [PubMed]
[18] Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S. and Kauffman, R.E. (2003) Developmental Pharmacology—Drug Disposition, Action, and Therapy in Infants and Children. New England Journal of Medicine, 349, 1157-1167. [Google Scholar] [CrossRef] [PubMed]
[19] Matalová, P., Urbánek, K. and Anzenbacher, P. (2016) Specific Features of Pharmacokinetics in Children. Drug Metabolism Reviews, 48, 70-79. [Google Scholar] [CrossRef] [PubMed]
[20] van Groen, B.D., Pilla Reddy, V., Badée, J., Olivares‐Morales, A., Johnson, T.N., Nicolaï, J., et al. (2020) Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium. Clinical and Translational Science, 14, 29-35. [Google Scholar] [CrossRef] [PubMed]
[21] Liu, G., Slater, N. and Perkins, A. (2017) Epilepsy: Treatment Options. American Family Physician, 96, 87-96.
[22] Shih, J.J., Whitlock, J.B., Chimato, N., Vargas, E., Karceski, S.C. and Frank, R.D. (2017) Epilepsy Treatment in Adults and Adolescents: Expert Opinion, 2016. Epilepsy & Behavior, 69, 186-222. [Google Scholar] [CrossRef] [PubMed]
[23] Verrotti, A., Striano, P., Iapadre, G., Zagaroli, L., Bonanni, P., Coppola, G., et al. (2018) The Pharmacological Management of Lennox-Gastaut Syndrome and Critical Literature Review. Seizure, 63, 17-25. [Google Scholar] [CrossRef] [PubMed]
[24] Wirrell, E.C., Hood, V., Knupp, K.G., Meskis, M.A., Nabbout, R., Scheffer, I.E., et al. (2022) International Consensus on Diagnosis and Management of Dravet Syndrome. Epilepsia, 63, 1761-1777. [Google Scholar] [CrossRef] [PubMed]
[25] Kapur, J., Elm, J., Chamberlain, J.M., Barsan, W., Cloyd, J., Lowenstein, D., et al. (2019) Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. New England Journal of Medicine, 381, 2103-2113. [Google Scholar] [CrossRef] [PubMed]
[26] Chamberlain, J.M., Kapur, J., Shinnar, S., Elm, J., Holsti, M., Babcock, L., et al. (2020) Efficacy of Levetiracetam, Fosphenytoin, and Valproate for Established Status Epilepticus by Age Group (ESETT): A Double-Blind, Responsive-Adaptive, Randomised Controlled Trial. The Lancet, 395, 1217-1224. [Google Scholar] [CrossRef] [PubMed]
[27] Guo, H., Jing, X., Sun, J., Hu, Y., Xu, Z., Ni, M., et al. (2019) Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. Current Pharmaceutical Design, 25, 343-351. [Google Scholar] [CrossRef] [PubMed]
[28] Perucca, E. (2002) Pharmacological and Therapeutic Properties of Valproate: A Summary after 35 Years of Clinical Experience. CNS Drugs, 16, 695-714. [Google Scholar] [CrossRef] [PubMed]
[29] Gerstner, T., Büsing, D., Bell, N., Longin, E., Kasper, J., Klostermann, W., et al. (2007) Valproic Acid-Induced Pancreatitis: 16 New Cases and a Review of the Literature. Journal of Gastroenterology, 42, 39-48. [Google Scholar] [CrossRef] [PubMed]
[30] Bischof, M.C.M., Stadelmann, M.I.E., Janett, S., Bianchetti, M.G., Camozzi, P., Goeggel Simonetti, B., et al. (2023) Valproic Acid-Associated Acute Pancreatitis: Systematic Literature Review. Journal of Clinical Medicine, 12, Article 6044. [Google Scholar] [CrossRef] [PubMed]
[31] Jahromi, S.R., Togha, M., Fesharaki, S.H., Najafi, M., Moghadam, N.B., Kheradmand, J.A., et al. (2011) Gastrointestinal Adverse Effects of Antiepileptic Drugs in Intractable Epileptic Patients. Seizure, 20, 343-346. [Google Scholar] [CrossRef] [PubMed]
[32] Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J.P., Sills, G., et al. (2021) The SANAD II Study of the Effectiveness and Cost-Effectiveness of Valproate versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial. The Lancet, 397, 1375-1386. [Google Scholar] [CrossRef] [PubMed]
[33] Kılıç, B., Serdaroğlu, E., Polat, B.G., İnce, T., Esenülkü, G., Topçu, Y., et al. (2022) Trends in the Choice of Antiseizure Medications in Juvenile Myoclonic Epilepsy: A Retrospective Multi-Center Study from Turkey between 2010 and 2020. Seizure: European Journal of Epilepsy, 99, 48-53. [Google Scholar] [CrossRef] [PubMed]
[34] Brigo, F. and Igwe, S.C. (2017) Ethosuximide, Sodium Valproate or Lamotrigine for Absence Seizures in Children and Adolescents. Cochrane Database of Systematic Reviews, 2, CD003032. [Google Scholar] [CrossRef] [PubMed]
[35] Silvennoinen, K., de Lange, N., Zagaglia, S., Balestrini, S., Androsova, G., Wassenaar, M., et al. (2019) Comparative Effectiveness of Antiepileptic Drugs in Juvenile Myoclonic Epilepsy. Epilepsia Open, 4, 420-430. [Google Scholar] [CrossRef] [PubMed]
[36] Nanau, R.M. and Neuman, M.G. (2013) Adverse Drug Reactions Induced by Valproic Acid. Clinical Biochemistry, 46, 1323-1338. [Google Scholar] [CrossRef] [PubMed]
[37] Yamamoto, Y., Takahashi, Y., Imai, K., Mishima, N., Yazawa, R., Inoue, K., et al. (2013) Risk Factors for Hyperammonemia in Pediatric Patients with Epilepsy. Epilepsia, 54, 983-989. [Google Scholar] [CrossRef] [PubMed]
[38] Zhu, J., Lu, J., Shen, X., He, Y., Xia, H., Li, W., et al. (2023) SCN1A Polymorphisms and Haplotypes Are Associated with Valproic Acid Treatment Outcomes in Chinese Children with Epilepsy. Pediatric Neurology, 146, 55-64. [Google Scholar] [CrossRef] [PubMed]
[39] Fan, D., Miao, J., Fan, X., Wang, Q. and Sun, M. (2019) Effects of Valproic Acid on Bone Mineral Density and Bone Metabolism: A Meta-Analysis. Seizure, 73, 56-63. [Google Scholar] [CrossRef] [PubMed]
[40] Kumar, R., Vidaurre, J. and Gedela, S. (2019) Valproic Acid-Induced Coagulopathy. Pediatric Neurology, 98, 25-30. [Google Scholar] [CrossRef] [PubMed]
[41] Gerstner, T., Teich, M., Bell, N., Longin, E., Dempfle, C., Brand, J., et al. (2006) Valproate‐Associated Coagulopathies Are Frequent and Variable in Children. Epilepsia, 47, 1136-1143. [Google Scholar] [CrossRef] [PubMed]
[42] Lee, Y.J., Kim, T., Bae, S.H., Kim, Y., Han, J.H., Yun, C., et al. (2013) Levetiracetam Compared with Valproic Acid for the Prevention of Postoperative Seizures after Supratentorial Tumor Surgery: A Retrospective Chart Review. CNS Drugs, 27, 753-759. [Google Scholar] [CrossRef] [PubMed]
[43] Kaczorowska-Hac, B., Matheisel, A., Maciejka-Kapuscinska, L., Wisniewski, J., Alska, A., Adamkiewicz-Drozynska, E., et al. (2012) Anemia Secondary to Valproic Acid Therapy in a 13-Year-Old Boy: A Case Report. Journal of Medical Case Reports, 6, Article No. 239. [Google Scholar] [CrossRef] [PubMed]

为你推荐